Market revenue in 2023 | USD 272.2 million |
Market revenue in 2030 | USD 408.1 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.07% in 2023. Horizon Databook has segmented the Middle East & Africa blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
MEA countries are increasingly adopting molecular and genetic testing into their diagnostic protocols. These technologies allow more precise classification of hematologic malignancies, aiding in treatment decision-making and prognostication.
Moreover, the increasing number of clinical trials and research initiatives is driving innovation in blood cancer diagnostics within the MEA region. Academic institutions, research centers, and pharmaceutical companies are conducting clinical trials to evaluate novel diagnostic technologies, biomarkers, and therapeutic interventions for hematologic malignancies.
Participation in international collaborative research networks and initiatives such as the Global Initiative for Cancer Registry Development (GICR) & the African Cancer Registry Network (AFCRN) are also expanding research opportunities and advancing knowledge in blood cancer diagnostics specific to MEA population.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa blood cancer diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account